Market Capitalization

With its strategic pivot to high-growth Med Tech paying off, all eyes are on AngioDynamics' CEO presentation at the upcoming Leerink healthcare conference.

Amid record financials and new AI breakthroughs, Cadence's CEO will address investors at a key conference to outline the firm's pivotal role in the AI era.

With cash to last until 2027 but mounting losses, Alector stakes its future on its ABC platform and a pivotal Alzheimer's trial milestone.

With record revenue and key battery tech milestones met, Enovix is on the brink of powering smartphones, but manufacturing hurdles and cash burn remain.

A private market index tracking tech giants like SpaceX surged nearly 200% in 14 months, raising questions about a new, exclusive tier of wealth creation.

Facing financial headwinds, Mint Inc. pivots into the high-stakes world of AI, unveiling the FLOKI Minibot M1, a personalized companion for Asia.

Struggling biotech Jupiter Neurosciences presents its Parkinson's drug to elite investors at Mar-a-Lago, betting its hybrid business model can win funding.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

While many cannabis firms struggle, Greenway Greenhouse reports a 40% revenue jump, expanding margins, and its fifth straight quarter of positive EBITDA.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

The diabetes tech firm secures major funding for innovation and acquisitions, using a savvy financial strategy to protect current shareholder value.

With its transformative Lanteris acquisition complete, all eyes are on Intuitive Machines' upcoming financial results for clues to its future as a space prime.

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

The legacy brand blends heritage, market strategy, and conservation with its new 8-year bourbon, inspired by 19th-century decanters and now available nationwide.

The Raine Group hires Credit Suisse veteran Anthony Kontoleon, signaling a major push to dominate TMT advisory ahead of an anticipated tech boom.

Cutting Horse, led by operators behind billion-dollar brands, exceeds its target to deploy capital and hands-on expertise to founder-led businesses.

AgTech innovator Agroz Inc. faces a Nasdaq delisting warning. With 180 days to recover, its future hinges on balancing advanced tech with market realities.

Tradewinds Universal aims to consolidate the fragmented $8B adult club scene with Peppermint Hippo, but regulatory hurdles and market risks loom large.